A retrospective analysis of triptan and dhe use for basilar and hemiplegic migraine
ConclusionIn this retrospective study, triptans and DHE were used with no reported, subsequent acute/subacute ischemic vascular events for the abortive treatment of migraines with basilar and hemiplegic‐type features. Although the small sample sizes generated theoretical statistical event rates of 4.5% for BM and 23% for HM, there has been no clear evidence that BM and HM carry an actual elevated risk for vascular events compared with migraine with aura.
Source: Headache: The Journal of Head and Face Pain - Category: Neurology Authors: Paul G. Mathew, Regina Krel, Bhuvin Buddhdev, Hossein Ansari, Shivang G. Joshi, Warren D. Spinner, Brad C. Klein Tags: Research Submissions Source Type: research
More News: Aphasia | Ataxia | Clinical Trials | Dystonia | Headache | Heart Attack | Ischemic Stroke | Migraine | Neurology | Pain | Statistics | Stroke | Study | Vertigo